TNF-α up-regulates CXCL10 level within CC cells by p38 MAPK, NK-κB and PI3K/Akt pathways. (A) NF-κB pathway inhibitor (BAY11-7082, BAY; targeting NF-κB), a p38 pathway inhibitor (SB203580, SB; targeting p38 MAPK), a PI3K pathway inhibitor (LY294002, LY; targeting PI3K) or an Akt pathway inhibitor (MK-2206 2HCI, MK; targeting Akt) was used to treat SW480/SW620 cells for 30 min before 24 h of 20 ng/ml TNF-α stimulation. At 24 h later, CXCL10 mRNA and protein levels were measured through qPCR and ELISA. (B) BAY, SB, LY, or MK was used to treat SW480/SW620 cells for 30 min together or separately before stimulation with 20 ng/ml TNF-α. At 24 h later, CXCL10 mRNA and protein expression was detected through qPCR and ELISA. (C) p-p38/p38, p-Akt/Akt and p-PI3K/PI3K protein levels within SW620 cells stimulated by 20 ng/ml TNF-α were detected through WB analysis. (D) p-p65, p-IKKα/β and p-IκBα protein levels within SW620 cells stimulated by 20 ng/ml TNF-α were detected through WB analysis. (E) IKKα, IKKβ, p65 and IκBα protein levels cytoplasm and nucleus of SW620 cells after TNF-α (20 ng/ml) stimulation were measured through WB analysis. (F) BAY, SB, LY, or MK was used to treat SW620 cells for 30 min together or separately before stimulation using TNF-α (20 ng/ml). At 2 h later, p-p65, p-p38, p-PI3K, and p-Akt protein levels were measured through WB assay in SW620 cells. The anti-GAPDH and anti-Lamin B antibody were used as the internal control, and every bar chart stand for mean ±SD (n=3). *p < 0.05, **p < 0.01 by Sidak multiple comparison test.